Evidence map›Paper›PMID 27566066›Full record

ArticleBMC cancer2016

Changes in the in vitro activity of platinum drugs when administered in two aliquots.

Zaynab Al-Eisawi, Philip Beale, Charles Chan, Jun Qing Yu, Nicholas Proschogo, Mark Molloy, Fazlul Huq

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Zaynab Al-EisawiDiscipline of Biomedical Science, Sydney Medical School, University of Sydney, Sydney, NSW, 2141, Australia.
Philip BealeSydney Cancer Centre, Concord Hospital, Sydney, NSW, 2139, Australia.
Charles ChanDepartment of Pathology, Concord Hospital, Sydney, NSW, 2139, Australia.
Jun Qing YuDiscipline of Biomedical Science, Sydney Medical School, University of Sydney, Sydney, NSW, 2141, Australia.
Nicholas ProschogoMass Spectrometry Unit, School of Chemistry, University of Sydney, Sydney, NSW, 2006, Australia.
Mark MolloyAustralian Proteome Analysis Facility, Macquarie University, Sydney, NSW, 2109, Australia.
Fazlul HuqDiscipline of Biomedical Science, Sydney Medical School, University of Sydney, Sydney, NSW, 2141, Australia. Fazlul.Huq@sydney.edu.au.
University of Sydney · AUConcord Repatriation General Hospital · AUAustralian Genome Research Facility · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe management of ovarian cancer remains a challenge. Because of the lack of early symptoms, it is often diagnosed at a late stage when it is likely to have metastasized beyond ovaries. Currently, platinum based chemotherapy is the primary treatment for the disease. However acquired drug resistance remains an on-going problem. As cisplatin brings about apoptosis by intrinsic and extrinsic pathways, this study aimed to determine changes in activity of platinum drugs when administered in two aliquots as against a bolus and sought to determine association with changes in GSH, speciation of platinum drugs and changes in protein expression.

methodsThe efficacy of administering cisplatin, carboplatin and oxaliplatin in two aliquots with a time gap was investigated in ovarian A2780, A2780(cisR), A2780(ZD0473R) and SKOV-3 cell lines. The cellular accumulation of platinum, level of platinum - DNA binding and cellular glutathione level were determined, and proteomic studies were carried out to identify key proteins associated with platinum resistance in ovarian A2780(cisR) cancer cell line.

resultsMuch greater cell kill was observed with solutions left standing at room temperature than with freshly prepared solutions, indicating that the increase in activity on ageing was related to speciation of the drug in solution. Proteomic studies identified 72 proteins that were differentially expressed in A2780 and A2780(cisR) cell lines; 22 of them were restored back to normal levels as a result of synergistic treatments, indicating their relevance in enhanced drug action.

conclusionsThe proteins identified are relevant to several different cellular functions including invasion and metastasis, cell cycle regulation and proliferation, metabolic and biosynthesis processes, stress-related proteins and molecular chaperones, mRNA processing, cellular organization/cytoskeleton, cellular communication and signal transduction. This highlights the multifactorial nature of platinum resistance in which many different proteins with diverse functions play key roles. This means multiple strategies can be harnessed to overcome platinum resistance in ovarian cancer. The results of the studies can be significant both from fundamental and clinical view points.

Indexed as

Ovarian NeoplasmsAntineoplastic AgentsApoptosisCarboplatinCell Line, TumorCell SurvivalCisplatinDrug Resistance, NeoplasmFemaleHumansIn Vitro TechniquesOrganoplatinum CompoundsOxaliplatinProteomicsSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAntineoplastic AgentsCarboplatinCisplatinOrganoplatinum CompoundsOxaliplatinAging effectCarboplatin (CB)Cisplatin (CS)Drug combinationDrug resistanceDrug uptakeOxaliplatin (OX)Synergism

Identifiers

PMID27566066
PMCPMC5002105
OpenAlexW2514794694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.